MX2011009312A - Formulaciones de anticuerpos humanizados anti-cd19. - Google Patents

Formulaciones de anticuerpos humanizados anti-cd19.

Info

Publication number
MX2011009312A
MX2011009312A MX2011009312A MX2011009312A MX2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A
Authority
MX
Mexico
Prior art keywords
humanized anti
antibody formulations
cdc
apoptosis
chimeric
Prior art date
Application number
MX2011009312A
Other languages
English (en)
Spanish (es)
Inventor
Monika Sharma
Ambarish Shah
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2011009312A publication Critical patent/MX2011009312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2011009312A 2009-03-06 2010-03-08 Formulaciones de anticuerpos humanizados anti-cd19. MX2011009312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15815309P 2009-03-06 2009-03-06
PCT/US2010/026492 WO2010102276A2 (en) 2009-03-06 2010-03-08 Humanized anti-cd19 antibody formulations

Publications (1)

Publication Number Publication Date
MX2011009312A true MX2011009312A (es) 2012-02-29

Family

ID=42710248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009312A MX2011009312A (es) 2009-03-06 2010-03-08 Formulaciones de anticuerpos humanizados anti-cd19.

Country Status (12)

Country Link
US (1) US20120148576A1 (enExample)
EP (1) EP2403532A4 (enExample)
JP (1) JP2012519712A (enExample)
KR (1) KR20110125664A (enExample)
CN (1) CN102413839A (enExample)
AU (1) AU2010221099A1 (enExample)
BR (1) BRPI1013237A2 (enExample)
CA (1) CA2754266A1 (enExample)
MX (1) MX2011009312A (enExample)
RU (1) RU2011140486A (enExample)
WO (1) WO2010102276A2 (enExample)
ZA (1) ZA201106480B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
MY161534A (en) * 2010-05-25 2017-04-28 Genentech Inc Methods of purifying polypeptides
US20130195851A1 (en) * 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013138244A2 (en) * 2012-03-12 2013-09-19 Medimmune, Llc Treatment of multiple sclerosis with anti-cd19 antibody
EP2841128A4 (en) * 2012-04-23 2015-11-25 Zogenix Inc PISTON CLOSURES FOR MEDICINAL PACKAGING CAPSULES
BR112015000657B1 (pt) * 2012-07-13 2023-12-05 The Trustees Of The University Of Pennsylvania Uso de uma célula geneticamente modificada para expressar um car
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
BR112015022210A8 (pt) * 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
SG11201607306PA (en) * 2014-04-07 2016-09-29 Seattle Genetics Inc Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CA2985001A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017015783A1 (en) * 2015-07-24 2017-02-02 Shanghai Sidansai Biotechnology Co., Ltd Humanized anti-cd19 antibody and use thereof
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
SG11201810429UA (en) * 2016-06-27 2018-12-28 Morphosys Ag Anti-cd19 antibody formulations
EP3330289A1 (en) * 2016-12-02 2018-06-06 Friedrich-Alexander-Universität Erlangen-Nürnberg A cd33-, cd16- and cd123-specific single chain triplebody
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
CA3083936C (en) * 2017-12-06 2022-08-23 Abclon Inc. Anti-cd19 antibody or antigen-binding fragment and cd19-specific chimeric antigen receptor comprising the same
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
SG11202111429UA (en) * 2019-04-24 2021-11-29 Viela Bio Inc Use of an anti-cd19 antibody to treat autoimmune disease
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
KR20220092578A (ko) * 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
KR20230127292A (ko) * 2020-12-30 2023-08-31 아이-맵 바이오파마 컴파니 리미티드 항-cd73 항체의 제제
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
CN113208810B (zh) * 2021-05-18 2022-04-12 南方医科大学深圳医院 一种用于smile术透镜染色低温分离液的超声波给药装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1648512A4 (en) * 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
CN103694349A (zh) * 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用

Also Published As

Publication number Publication date
BRPI1013237A2 (pt) 2019-09-24
JP2012519712A (ja) 2012-08-30
KR20110125664A (ko) 2011-11-21
AU2010221099A1 (en) 2011-09-22
EP2403532A2 (en) 2012-01-11
US20120148576A1 (en) 2012-06-14
CN102413839A (zh) 2012-04-11
RU2011140486A (ru) 2013-04-20
CA2754266A1 (en) 2010-09-10
ZA201106480B (en) 2012-06-27
WO2010102276A2 (en) 2010-09-10
WO2010102276A3 (en) 2010-11-11
EP2403532A4 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
NL301196I2 (nl) inebilizumab
AU2013232386A8 (en) Treatment of multiple sclerosis with anti-CD19 antibody
PH12018501554A1 (en) Ror1 antibody compositions and related methods
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
GEP20227438B (en) Pd-1-binding molecules and methods of use thereof
EP3712178A4 (en) ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP4477269A3 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
WO2016081746A8 (en) Antibodies comprising modified heavy constant regions
TN2014000107A1 (en) Anti-aplhabetatcr antibody
UA92504C2 (en) Anti-myostatin monoclonal antibody
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
HK1203372A1 (en) Chimeric therapeutic anti - cd37 antibodie hh1
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal